During the three months ended March 31, 2021 and 2020, APC paid approximately $0.5 million and $0.6 million, respectively, to PMIOC for provider services, which is accounted for under the equity method based on 40% equity ownership interest held by APC (see Note 4).

During the three months ended March 31, 2021 and 2020, APC paid approximately $1.6 and $1.8 million, respectively, to DMG for provider services, which is accounted for under the equity method based on 40% equity ownership interest held by APC (see Note 4).

During the three months ended March 31, 2021 and 2020, APC paid approximately $21,700 and $39,800, respectively, to Advanced Diagnostic Surgery Center for services as a provider. Advanced Diagnostic Surgery Center shares common ownership with certain board members of APC.

During the three months ended March 31, 2021 and 2020, APC paid approximately $33,100 and 50,900, respectively, to Fresenius Medical Care (“Fresenius”) and their subsidiaries for services as a provider. During the three months ended March 31, 2021 and 2020, APAACO paid approximately $0.2 million and $0.1 million, respectively, to Fresenius and its subsidiaries for services as a provider. One of the Company’s board members is an officer of Fresenius.

During the three months ended March 31, 2021 and 2020, APC paid approximately $20,700 and $0, respectively, to Fulgent Genetics, Inc. for services as a provider. Fulgent Genetics, Inc. shared a common board member with the Company.

During the three months ended March 31, 2021 and 2020, APC paid an aggregate of approximately $7.4 million and $7.3 million to shareholders of APC, respectively, which included approximately $1.7 million and $1.7 million, respectively, to shareholders who are also officers of APC.

During the three months ended March 31, 2021 and 2020, the Company paid approximately $0 and $0.1 million, respectively, to Critical Quality Management Corporation (“CQMC”) for an office lease. CQMC shares common ownership with certain board members of APC.

For the three months ended March 31, 2021 and 2020, SCHC paid approximately $0.1 million and $0.1 million, respectively, to Numen, LLC (“Numen”) for an office lease. Numen is owned by a shareholder of APC.

During the years ended March 31, 2021 and 2020, APC paid approximately $0.4 million and $0.4 million, respectively, to One MSO, Inc. (“One MSO”) for an office lease, which is accounted for under the equity method based on 50% equity ownership interest held by APC (see Note 4).

The Company has agreements with HSMSO, Aurion Corporation (“Aurion”), and AHMC Healthcare (“AHMC”) for services provided to the Company. One of the Company’s board members is an officer of AHMC, HSMSO, and Aurion. Aurion is also partially owned by one of the Company’s board members. The following table sets forth fees incurred and revenue earned related to AHMC, HSMSO, and Aurion (in thousands):


	Three Months Ended March 31,
	2021		2020
AHMC – Risk pool, capitation, claims payment	$	13,097	$	11,999
HSMSO – Management fees, net	(77)		(132)
Aurion – Management fees	(75)		(75)

Receipts, net	$	12,945	$	11,792

The Company and AHMC have a risk-sharing agreement with certain AHMC hospitals to share the surplus and deficits of each of the hospital pools. During the three months ended March 31, 2021 and 2020, the Company has recognized risk pool revenue under this agreement of $16.9 million and $12.0 million, respectively, for which $62.6 million and $45.3 million remained outstanding as of March 31, 2021 and December 31, 2020, respectively.

During the three months ended March 31, 2021 and 2020, NMM paid approximately $44,300 and $26,600, respectively, to an ApolloMed board member for consulting services.

In addition, affiliates wholly-owned by the Company’s officers, including the Company’s Co-CEOs, Dr. Kenneth Sim and Dr. Thomas Lam, are reported in the accompanying consolidated statements of income on a consolidated basis, together with the

Company’s subsidiaries, and therefore, the Company does not separately disclose transactions between such affiliates and the Company’s subsidiaries as related-party transactions.

For equity method investments, loans receivable and line of credits from related parties, see Notes 4, 5, and 8, respectively.